CLYM logo

Climb Bio, Inc.

CLYM
Healthcare|Biotechnology|US
$10.29
+1.42 (+16.01%)
DCF Value
$0.49
Tangible Book / Share
$2.85
Cash / Share
$2.57
Next Earnings Report
Mar 4, 2027
EPS est. -$0.21
Financing Filings (last 12 months)
1
Shelf registrations / offering prospectuses — latest Nov 5, 2026 (S-3ASR). Possible dilution.

Upcoming Data Readouts (4)

Apr 2027
Est. completion
P1Systemic Lupus Erythematosus
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07011043n=30
Aug 2027
Est. completion
P1P2Immune Thrombocytopenia (ITP)
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
NCT07043946n=24
Sep 2027
Est. completion
P1P2Systemic Lupus Erthematosus
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07564596n=30
Oct 2027
Est. completion
P2Primary Membranous Nephropathy
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
NCT07096843n=45

Recent Press Releases

Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
Nov 5, 2026 · GlobeNewsWire
Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
Nov 4, 2026 · GlobeNewsWire
Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 2, 2026 · GlobeNewsWire
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Oct 24, 2026 · GlobeNewsWire
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
Oct 23, 2026 · GlobeNewsWire
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
Oct 2, 2026 · GlobeNewsWire
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
Sep 3, 2026 · GlobeNewsWire
Climb Bio to Present at Upcoming Investor Conferences
Sep 2, 2026 · GlobeNewsWire

SEC Filings (8)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 5, 2026S-3ASRShelf registrationDocumentIndex
Nov 5, 202610-QQuarterly reportDocumentIndex
Nov 5, 20268-KMaterial eventDocumentIndex
Oct 28, 2026SC 13GPassive 5%+ stakeDocumentIndex
Oct 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Oct 26, 20268-KMaterial eventDocumentIndex
Oct 23, 20268-KMaterial eventDocumentIndex